Matthew P Goetz

Matthew P Goetz

UNVERIFIED PROFILE

Are you Matthew P Goetz?   Register this Author

Register author
Matthew P Goetz

Matthew P Goetz

Publications by authors named "Matthew P Goetz"

Are you Matthew P Goetz?   Register this Author

100Publications

3690Reads

30Profile Views

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.

Breast Cancer Res Treat 2019 Aug 22;176(3):709-716. Epub 2019 May 22.

Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05264-2DOI Listing
August 2019

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.

J Clin Oncol 2019 Aug 18;37(22):1982-1983. Epub 2019 Jun 18.

Matthew P. Goetz, MD and Vera J. Suman, PhD, Mayo Clinic, Rochester, MN; Yusuke Nakamura, MD, PhD and Kazuma Kiyotani, PhD, Cancer Precision Medicine Center, Tokyo, Japan; V. Craig Jordan, PhD, DSc, The University of Texas MD Anderson Cancer Center, Houston, TX; and James N. Ingle, MD, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/JCO.19.00504
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675592PMC
August 2019

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

N Engl J Med 2019 06 3;380(25):2395-2405. Epub 2019 Jun 3.

From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); University of Texas, San Antonio (P.M.R.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O., J.A.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); the National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and the University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and the University of Hawaii Cancer Center, Honolulu (J.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709671PMC
June 2019

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.

Oncotarget 2019 Jun 11;10(39):3924-3930. Epub 2019 Jun 11.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570466PMC
June 2019

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.

Breast Cancer Res 2019 04 3;21(1):47. Epub 2019 Apr 3.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1130-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448248PMC
April 2019

The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer.

Cancer Metab 2019 24;7. Epub 2019 Jan 24.

1Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40170-018-0193-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345044PMC
January 2019

Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway.

Cell Metab 2018 12 30;28(6):833-847.e8. Epub 2018 Aug 30.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2018.08.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281770PMC
December 2018

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med 2018 Jul 3;379(2):111-121. Epub 2018 Jun 3.

From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Chicago Stritch School of Medicine, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L., J.A.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); University of Texas, San Antonio (P.M.R.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and University of Hawaii Cancer Center, Honolulu (J.L.B.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804710
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172658PMC
July 2018

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

N Engl J Med 2018 Jul 4;379(2):122-137. Epub 2018 Jun 4.

From the Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Newcastle, NSW (P.A.F.), and the University of Sydney, Sydney (A.S.C.) - all in Australia; the Institute of Oncology of Southern Switzerland, Ospedale San Giovanni, Bellinzona (O.P.), Breast Cancer St. Gallen, St. Gallen (T.R.), and the International Breast Cancer Study Group Coordinating Center (R.M., M.R.-P., B.R., A.S.C.), University Hospital Inselspital (M.R.-P.), Bern - all in Switzerland; the University of Chicago Medical Center, Chicago (G.F.F.); the University of Calgary, Calgary, AB, Canada (B.A.W.); the Division of Medical Senology, European Institute of Oncology (M.C.), and the European Institute of Oncology and International Breast Cancer Study Group (A.G.), Milan, Ospedale Papa Giovanni XXIII, Bergamo (C.T.), Azienda Socio Sanitaria Territoriale Sette Laghi-Ospedale di Circolo and Fondazione Macchi, Varese (G.P.), Medical Oncology and Cancer Prevention, IRCCS, National Cancer Institute, Aviano (F.P., S.S.), the Department of Medicine, School of Medical Oncology, University of Udine, Udine (F.P.), Salvatore Maugeri Foundation, Pavia (L.P.), and the Hospital of Prato-Azienda Unità Sanitaria Locale Toscana Centro, Prato (A.D.L.) - all in Italy; the National Institute of Oncology, Budapest, Hungary (I.L.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.); University Hospital 12 de Octubre, Madrid (E.C.), Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (M.B.), and Instituto Valenciano de Oncologia, Valencia (M.A.C.) - all in Spain; the Susan F. Smith Center for Women's Cancers (H.J.B., E.P.W.) and the International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology (R.D.G., M.M.R.), Dana-Farber Cancer Institute, Harvard Medical School, the Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation (R.D.G.) - all in Boston; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France (H.R.B., M.D.); the Angeles Clinic and Research Institute, Santa Monica, CA (S.M.); Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond (C.E.G.); Mayo Clinic, Rochester, MN (M.P.G., J.N.I.); Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (V.S.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (N.E.D.); Weston Park Hospital, Sheffield, United Kingdom (R.C.); and the Department of Obstetrics and Gynecology, University Medical Center, Regensburg, Germany (S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457PMC
July 2018

HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data.

BMC Bioinformatics 2018 07 17;19(1):271. Epub 2018 Jul 17.

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-018-2260-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050683PMC
July 2018

Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:65-77

From the Stanford Comprehensive Cancer, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Rochester, MN.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200715
Publisher Site
http://dx.doi.org/10.1200/EDBK_200715DOI Listing
May 2018

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.

Breast Cancer Res Treat 2018 Apr 30;168(3):639-647. Epub 2017 Dec 30.

Division of Medical Oncology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4616-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842248PMC
April 2018

Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity.

Cell Rep 2018 02;22(6):1365-1373

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.01.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826573PMC
February 2018

The development of endoxifen for breast cancer.

Authors:
Matthew P Goetz

Clin Adv Hematol Oncol 2018 Feb;16(2):102-105

Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
February 2018

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

J Clin Oncol 2017 Nov 2;35(32):3638-3646. Epub 2017 Oct 2.

Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6155
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6155DOI Listing
November 2017

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer.

Oncotarget 2017 Nov 11;8(57):96506-96521. Epub 2017 Oct 11.

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/21787
Publisher Site
http://dx.doi.org/10.18632/oncotarget.21787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722501PMC
November 2017

Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.

Ann Surg Oncol 2017 Oct 1;24(10):2989-2998. Epub 2017 Aug 1.

Department of Surgery, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-017-5930-3DOI Listing
October 2017

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

J Clin Oncol 2017 Oct 30;35(30):3391-3400. Epub 2017 Aug 30.

Matthew P. Goetz, Vera J. Suman, Joel M. Reid, Don W. Northfelt, Michael A. Mahr, Andrew T. Ralya, Mary Kuffel, Sarah A. Buhrow, Stephanie L. Safgren, Renee M. McGovern, John Black, Travis Dockter, Tufia Haddad, Charles Erlichman, Alex A. Adjei, Dan Visscher, Benjamin R. Kipp, Minetta C. Liu, John R. Hawse, Matthew M. Ames, and James N. Ingle, Mayo Clinic, Rochester, MN; Zachary R. Chalmers and Garrett Frampton, Foundation Medicine, Cambridge, MA; and John R. Hawse, James H. Doroshow, Jerry M. Collins, and Howard Streicher, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.3246
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.3246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648176PMC
October 2017

A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2017 Jun 5;79(6):1221-1227. Epub 2017 May 5.

Division of Medical Oncology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3322-9DOI Listing
June 2017

Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?

Ann Surg Oncol 2017 Mar 4;24(3):614-617. Epub 2017 Jan 4.

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-016-5740-zDOI Listing
March 2017

Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.

J Clin Oncol 2016 11;34(32):3944-3945

Matthew P. Goetz, Mayo Clinic, Rochester, MN; Mark Ratain, The University of Chicago, Chicago, IL; and James N. Ingle, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.5214DOI Listing
November 2016

Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer.

J Clin Oncol 2016 06 21;34(17):1970-2. Epub 2016 Mar 21.

Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2312DOI Listing
June 2016

Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.

Mol Endocrinol 2016 Mar 11;30(3):382-98. Epub 2016 Feb 11.

Division of Clinical Pharmacology (M.-F.H., M.L., L.W., R.M.W.), Department of Molecular Pharmacology and Experimental Therapeutics, Division of Rheumatology (M.-F.H., T.B.), Department of Medicine, Division of Biomedical Statistics and Informatics (K.R.K.), Department of Health Sciences Research, and Division of Medical Oncology (M.P.G., J.N.I.), Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905; Division of Hematology/Oncology (P.E.G.), Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard University, Boston, Massachusetts 02114; National Cancer Institute of Canada Clinical Trials Group (L.E.S.), Kingston, Ontario, Canada K7L 3N6; and RIKEN Center for Integrative Medical Science (M.K.), Yokohama 230-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/me.2015-1267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771694PMC
March 2016

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2015 Aug 20;33(24):2695-704. Epub 2015 Jul 20.

Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Robert C. Bast, Ana M. Gonzalez-Angulo, and William F. Symmans, University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Texas Oncology, Dallas, TX; Massimo Cristofanilli, Thomas Jefferson University-Kimmel Cancer Center, Philadelphia, PA; Matthew P. Goetz and Minetta C. Liu, Mayo Clinic, Rochester, MN; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Elizabeth G. Hill, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC; Wanda Lucas, Georgetown University, Washington, DC; Ingrid A. Mayer, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN; and Lyndsay N. Harris, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.1459DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478102PMC
August 2015

Landscape of neoadjuvant therapy for breast cancer.

Ann Surg Oncol 2015 May 2;22(5):1408-15. Epub 2015 Mar 2.

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1245%2Fs10434-015-44
Web Search
http://link.springer.com/10.1245/s10434-015-4405-7
Publisher Site
http://dx.doi.org/10.1245/s10434-015-4405-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484769PMC
May 2015

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.

Pharmacogenet Genomics 2015 Apr;25(4):157-63

Departments of aOncology bMolecular Pharmacology and Experimental Therapeutics cBiostatistics dLaboratory Medicine, Mayo Clinic, Rochester, Minnesota eDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona fCambridge Isotope Laboratories Inc. gPhysical Sciences Inc., Andover, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356640PMC
April 2015

Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.

Toxicol Pathol 2014 Dec 26;42(8):1188-96. Epub 2014 Mar 26.

Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0192623314525688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177029PMC
December 2014

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

J Natl Cancer Inst 2014 Dec 8;107(2). Epub 2014 Dec 8.

Department of Oncology (MPG, MMA, JNI), Department of Health Sciences Research (VJS, KRK), and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, SLS, MK, MMA), Mayo Clinic, Rochester, MN; Department of Genetics, University of North Carolina, Chapel Hill, NC (GOS, CMP); Center for Personalized Therapeutics, University of Chicago, Chicago, IL (YN, NJC, MJR); Foundation Medicine Inc., Cambridge, MA (JXS, PJS, VAM, JSR, RY); Novartis Pharmaceuticals Corporation, East Hanover, NJ (DC); Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY (JSR); Division of Hematology/Oncology, Vanderbilt University, Nashville, TN (HG); Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (AMGA, OB); Department Breast Cancer Susceptibility and Pharmacogenomics, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, University Tuebingen, German Cancer Consortium (DKTK) and German Cancer Research (DKTK), Heidelberg, Germany (HB).Current affiliation of H. Gomez: Departamento de Medicina Oncologica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565524PMC
December 2014

Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

J Natl Cancer Inst 2014 Apr 3;106(5). Epub 2014 Apr 3.

Affiliations of authors: Department of Oncology (MPG, JNI) and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, RW), Mayo Clinic, Rochester, MN; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (HB); The University of Chicago, Chicago, IL (MJR, NJC, YN).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580553PMC
April 2014

Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts.

Clin Exp Metastasis 2013 Apr 15;30(4):407-15. Epub 2013 Feb 15.

Department of Experimental Pathology, Mayo Clinic College of Medicine, 200 First Street, S.W., 2-46 Stabile, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-012-9546-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619208PMC
April 2013

Update on CYP2D6 and Tamoxifen.

Authors:
Matthew P Goetz

Clin Adv Hematol Oncol 2013 Mar;11(3):178-80

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
March 2013

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

J Clin Oncol 2013 Jan 22;31(2):176-80. Epub 2012 Oct 22.

Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.44.6625
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.44.6625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731938PMC
January 2013

Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.

Breast Cancer Res 2012 Mar 12;14(2):R43. Epub 2012 Mar 12.

Department of Experimental Pathology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr3140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446377PMC
March 2012

Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.

J Cell Biochem 2012 Feb;113(2):711-23

Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.23443DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725124PMC
February 2012

CYP2D6 and tamoxifen: awaiting the denouement.

J Clin Oncol 2011 Dec 31;29(34):4589-90; author reply 4590-1. Epub 2011 Oct 31.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.38.8611DOI Listing
December 2011